קואט dvi 250
padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
קואט dvi 500
padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
קואט dvi 1000
padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
פאנדי 25 יח'מל (פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פאנדי 50 יח'מל ( פקטור 8 )
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פאנדי 100 יח'מל ( פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
אוקטאניין f 500 יח' בינל
dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).
אוקטאניין f 1000 יח' בינל
dover medical & scientific equipment ltd, israel - factor ix - אבקה וממס להכנת תמיסה להזרקה - factor ix 100 iu/ml - coagulation factor ix - coagulation factor ix - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).
אופטיוואט 500 iu
kamada ltd, israel - factor viii; von willebrand factor - אבקה להכנת תמיסה לזריקה - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).
אופטיוואט 1000 iu
kamada ltd, israel - factor viii; von willebrand factor - אבקה להכנת תמיסה לזריקה - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).